Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 07:00 ET | Source: Lungpacer Medical USA Inc.

Lungpacer Medical Announces First Enrollments in STARI Trial of Next-Generation Neurostimulation Therapy

Lungpacer Medical today announced the first six patients enrolled in the groundbreaking STARI clinical trial.
November 03, 2025 16:05 ET | Source: Abivax

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely...
November 03, 2025 11:54 ET | Source: Rendever

Rendever Receives Nearly $4.5 Million in NIH Funding to Overcome Social Isolation for Older Adults while Supporting Caregivers

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Rendever, the company leading the industry in immersive technology for aging, has secured nearly $4.5 million in grant funding from the National Institutes...
November 03, 2025 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

November 3, 2025 Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7...
October 29, 2025 09:30 ET | Source: SNS Insider pvt ltd

Clinical Trial Investigative Site Network Market Size to Hit USD 15.10 Billion by 2032, Growing at a CAGR of 6.96% - SNS Insider

Austin, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Clinical Trial Investigative Site Network Market Size & Growth Analysis According to SNS Insider, the global Clinical Trial Investigative Site Network...
October 29, 2025 08:31 ET | Source: PolarityBio

PolarityBio Announces Acceptance of Category III CPT® Code Application for Autologous Heterogeneous Skin Construct Graft by AMA CPT® Editorial Panel

SALT LAKE CITY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolarityBio, a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous regenerative...
October 27, 2025 07:30 ET | Source: MicrobiotiX

MicrobiotiX Receives IND Approval for Novel Bacteriophage Drug MP101

MicrobiotiX gains IND approval to initiate clinical trials for its pneumonia therapy designed to combat antibiotic-resistant superbugs.
October 22, 2025 08:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%

SINGAPORE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing...
October 21, 2025 04:00 ET | Source: AKAMPION

selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease

Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients si-544 is the first highly potent and selective Kv1.3 blocker...
October 21, 2025 03:27 ET | Source: Nxera Pharma

Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapiesHTL0039732, was found to be...